

Buy

Can Fin Homes Ltd.

20th November 2023

Buy

Target : 900

Stop Loss : 730

CMP : 778

Range : 778-780

Period : 1 Month

Tech Edge

Can Fin Homes Ltd. (CANFINHOME)

- ▲ We're seeing a mixed trend within the financials space wherein stocks from the housing finance basket are showing strength.
- ▲ Among the performers, Canfinhomes has set the ground for the resumption of the uptrend, after spending 5 months in a narrow range i.e. 730-795 zone.
- ▲ Technically, it has formed a strong base around the support zone of the neckline area of the previous consolidation range. And, the recent price action combined with an uptick in volumes is pointing towards a steady upmove. We thus recommend creating fresh longs in the mentioned range.



Open Calls

Running Recommendations					
Scrip Symbol	Rec. Date	Rec. Price	Closing Price (November 17, 2023)	SL	Target
RAMCOCEM	28-Aug-23	863	1006.55	960*	1070*
*Trail Stoploss					
**Target revised					

Performance of Closed Recommendations					
Scrip Symbol	Rec. Date	Rec. Price	Closing On	Return %	Remarks
HAVELLS	8-Sep-23	1418	20-Oct-23	-6.9	Exit at 1320
GRASIM	15-Jun-23	1798	20-Sep-23	7.9	Book profit at 1940
TATASTEEL	10-Jul-23	114	02-Aug-23	4.8	Book profit at 120
ICICIBANK	05-Jul-23	956	02-Aug-23	1.5	Book profit at 970
GAIL	19-Jul-23	110	31-Jul-23	7.3	Book profit at 118
HAVELLS	19-Apr-23	1230	23-Jun-23	6.9	Book profit at 1315
EXIDEIND	12-Apr-23	185	01-Jun-23	15.7	Book profit at 214
RAMCOCEM	22-May-23	840	01-Jun-23	7.7	Book profit at 905
NAUKRI	15-May-23	3958	17-May-23	-4.2	Exit at 3790
BERGEPAIN	26-Apr-23	602	12-May-23	6.3	Book profit at 640
MANAPPURAM	29-Mar-23	120.90	03-May-23	3.4	Book profit at 125
ABB	06-Mar-23	3445	11-Apr-23	-3.9	Exit at 3310
ABCAPITAL	02-Mar-23	153	16-Mar-23	-5.8	Exit at 144
EICHERMOT	15-Feb-23	3325	01-Mar-23	-7.0	Exit at 3090
GLENMARK	02-Nov-22	1764	27-Jan-23	-5.9	Exit at 1660
UBL	08-Dec-22	417	04-Jan-23	-5.3	Exit at 395
IGL	28-Nov-22	432	23-Dec-22	-6.4	Exit at 404
L&TFH	15-Dec-22	95	21-Dec-22	-6.3	Exit at 89
EXIDEIND	04-Nov-22	173.5	16-Dec-22	7.8	Book profit at 187
BHARATFORG	27-Oct-22	828	16-Dec-22	7.3	Book profit at 888
COFORGE	01-Dec-22	4160	09-Dec-22	-6.5	Exit at 3890
MCDOWELL-N	25-Oct-22	857	13-Dec-22	7.7	Book profit at 923
SUNPHARMA	29-Sep-22	938	03-Nov-22	11	Book profit at 1040
CROMPTON	25-Aug-22	401	24-Oct-22	-6.7	Exit at 374
TATACONSUM	29-Aug-22	805	11-Oct-22	-7.5	Exit at 745
IGL	09-Sep-22	424	03-Oct-22	-7.5*	Exit at 387
*Dividend added					

[Click here](#) for Past Performance archive



Research Team

Name	Email ID
Siddarth Bhamre	siddarth.bhamre@religare.com
Ajit Mishra	ajit.mishra@religare.com
Manoj M Vayalar	manoj.vayalar@religare.com
Nirvi Ashar	nirvi.ashar@religare.com
Gaurav Arora	gaurav.arora3@religare.com
Akshay Tiwari	akshay.tiwari@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Rohan Shah	rohan.shah@religare.com
Riddhika Mirajkar	riddhika.mirajkar@religare.com
Ashwani Harit	ashwani.harit@religare.com



Disclaimer

Before you use this research report , please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link : <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA)

[Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) below , are given separately]

S. No.	Statement	Answer	
		Yes	No
		Tick appropriate	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No

	I / we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No

	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest (if answer to F (a) above is Yes :

.....

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) above , are given below]

SS.No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No.

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

